Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Generative AI could boost biopharma R&D productivity by billions, according to McKinsey

By Brian Buntz | June 16, 2023

Female Scientist Using Microscope in Laboratory

[Image credit: Seventyfour/Adobe Stock]

Generative AI stands to add trillions of dollars of value to the world economy, according to a recent McKinsey report. The consultancy noted that about three-quarters of the value of generative AI spans four areas — customer operations, marketing and sales, software engineering and R&D. The latter could see a 12% annual lift in global functional spending as a result of generative AI, representing an approximately $328 billion windfall annually.

An evolution or revolution: UBS and McKinsey’s take on generative AI in biopharma

The investment bank UBS recently reached more muted conclusions, noting that generative AI would represent more of an evolution than a revolution for biopharma.

Conversely, McKinsey bets the technology could deliver productivity gains that account for 10% to 15% of overall R&D costs. This potential largely stems from the application of generative AI foundation models in what is known as generative design.

In the face of such perspectives, Adityo Prakash, CEO of Verseon, agrees with the transformative potential of AI but cautions against oversimplification. He underscores the need for a holistic approach to AI, taking into account the limitations of data. He points out a critical example in the conversion of chemical structure data. “If a lot of this data is just 2D chemical structures for a small molecule structure, what you’re supposed to do is turn that into 3D using tools that can generate a realistic 3D representation,” Prakash said. “The problem is that many people in this space often miss the details required for deploying AI.”

Beyond drug development: Generative AI’s impact on various industries

Indeed, many of McKinsey’s pronouncements extend beyond the pharma sector. The firm, for instance, projects the technology could automate tasks that now occupy about 60% to 70% of employees’ time across various industries. Ultimately, McKinsey estimates that “half of today’s work activities could be automated between 2030 and 2060,” roughly a decade earlier than in its earlier models suggested.

Prakash stressed that solving thorny drug development hurdles will require a cross-disciplinary approach. “To really solve the problem well, you need people who speak all of these languages fluently,” he said, referring to the various domains of expertise required in drug development – including data science, biology, chemistry, and AI. He suggests that a team combining a physicist, a mathematician and other backgrounds can potentially solve the problem better than siloed teams.

The aim is to expand what Lilly refers to as its “digital worker-equivalent workforce,” an idea intended to measure the time saved by employing technology in place of human labor. In an interview with Insider, Lilly CEO David Ricks stated that its initiatives, initiated in 2022 and encompassing more than 100 projects, are comparable to nearly 1.4 million hours of human effort, or roughly 160 years of round-the-clock work.

In response to the pharma giants’ embrace of AI, Prakash suggested that while these steps are commendable, it’s vital not to underestimate the challenges ahead or overstate the capabilities of AI alone. “We need to get there, and it’s a completely non-trivial task. AI is only one of many tools that are going to help,” Prakash said. “Just chanting ‘AI’ doesn’t get you there,” he stated.


Filed Under: Data science, Drug Discovery and Development, Industry 4.0, machine learning and AI
Tagged With: ai challenges, AI in Pharma, digital workforce, drug development, generative AI, mckinsey report, productivity gains, Verseon
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Abstract neural network
Inside IQVIA’s quest to build a multi-agent AI ‘dream team’ to transform clinical trials
Xaira and Verily co-founder ponders low-hanging fruit and blue-sky potential in FDA’s genAI rollout
Capgemini’s life-sciences lead says ROI and data security, not algorithms, will decide pharma’s AI future
Portrait of happy smiling mature middle aged professional business woman investor manager executive or lawyer attorney looking at camera at workplace working on laptop computer in office.
As FDA pushes agency-wide generative AI, pharma experience show similar tools can cut clinical study-report drafting time by 30% or more
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE